Ancora Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $151K | Sell |
798
-737
| -48% | -$139K | ﹤0.01% | 791 |
|
|
2026
Q1 | $303K | Sell |
1,535
-92
| -6% | -$17.7K | 0.01% | 623 |
|
|
2025
Q4 | $299K | Buy |
1,627
+1,010
| +164% | +$177K | 0.01% | 641 |
|
|
2025
Q3 | $94.6K | Buy |
617
+19
| +3% | +$2.88K | ﹤0.01% | 880 |
|
|
2025
Q2 | $83.6K | Buy |
598
+23
| +4% | +$3.22K | ﹤0.01% | 914 |
|
|
2025
Q1 | $84.5K | Sell |
575
-25
| -4% | -$3.62K | ﹤0.01% | 902 |
|
|
2024
Q4 | $78.6K | Buy |
600
+25
| +4% | +$3.5K | ﹤0.01% | 905 |
|
|
2024
Q3 | $89.5K | Hold |
575
| – | – | ﹤0.01% | 850 |
|
|
2024
Q2 | $89.6K | Sell |
575
-292
| -34% | -$43.9K | ﹤0.01% | 816 |
|
|
2024
Q1 | $117K | Buy |
867
+2
| +0.2% | +$265 | ﹤0.01% | 777 |
|
|
2023
Q4 | $117K | Hold |
865
| – | – | ﹤0.01% | 777 |
|
|
2023
Q3 | $117K | Sell |
865
-61
| -7% | -$8.33K | ﹤0.01% | 761 |
|
|
2023
Q2 | $132K | Buy |
926
+11
| +1% | +$1.62K | ﹤0.01% | 734 |
|
|
2023
Q1 | $127K | Buy |
915
+52
| +6% | +$7K | ﹤0.01% | 734 |
|
|
2022
Q4 | $117K | Sell |
863
-150
| -15% | -$18.8K | ﹤0.01% | 790 |
|
|
2022
Q3 | $111K | Buy |
1,013
+108
| +12% | +$13.7K | ﹤0.01% | 871 |
|
|
2022
Q2 | $120K | Sell |
905
-193
| -18% | -$25.3K | ﹤0.01% | 905 |
|
|
2022
Q1 | $146K | Hold |
1,098
| – | – | ﹤0.01% | 902 |
|
|
2021
Q4 | $128K | Hold |
1,098
| – | – | ﹤0.01% | 949 |
|
|
2021
Q3 | $132K | Sell |
1,098
-52
| -5% | -$6.05K | ﹤0.01% | 900 |
|
|
2021
Q2 | $138K | Hold |
1,150
| – | – | ﹤0.01% | 833 |
|
|
2021
Q1 | $114K | Buy |
1,150
+52
| +5% | +$5.23K | ﹤0.01% | 844 |
|
|
2020
Q4 | $110K | Sell |
1,098
-969
| -47% | -$103K | ﹤0.01% | 733 |
|
|
2020
Q3 | $227K | Buy |
2,067
+654
| +46% | +$72.7K | 0.01% | 584 |
|
|
2020
Q2 | $149K | Buy |
1,413
+344
| +32% | +$35.5K | 0.01% | 639 |
|
|
2020
Q1 | $95K | Hold |
1,069
| – | – | ﹤0.01% | 786 |
|
|
2019
Q4 | $107K | Buy |
+1,069
| New | +$101K | ﹤0.01% | 763 |
|
|
2018
Q4 | – | Sell |
-1,069
| Closed | -$85K | – | 653 |
|
|
2018
Q3 | $85K | Buy |
+1,069
| New | +$80.9K | ﹤0.01% | 791 |
|
|
2017
Q1 | – | Sell |
-302
| Closed | -$16K | – | 644 |
|
|
2016
Q4 | $16K | Buy |
+302
| New | +$17.1K | ﹤0.01% | 978 |
|
Other funds holding AZN
EP
IA
Ancora Advisors's AZN Position: Q2 2026 in Review
Ancora Advisors reduced its AstraZeneca (AZN) stake by 48% in Q2 2026, selling an estimated $139K and leaving 798 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #791.
Ancora Advisors first reported a position in AZN in Q4 2016 and has held it in 29 quarters since. The position peaked at $303K in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Ancora Advisors held 798 shares of AstraZeneca worth $151K as of Q2 2026.
- Ancora Advisors sold 737 AstraZeneca shares in Q2 2026, an estimated $139K.
- AstraZeneca made up ﹤0.01% of Ancora Advisors's portfolio in Q2 2026, its #791 holding.
- Ancora Advisors first reported a position in AstraZeneca in Q4 2016 and has held it in 29 quarters since.
- Ancora Advisors's AstraZeneca position peaked at $303K in Q1 2026.
- 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Ancora Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.